Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 4/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6530713 | 0.82 | KDM4E (0.37) | ADORA2BADORA2ATYMP | |
| SCHEMBL1070361 | 0.76 | ADORA2A (0.49) | ADORA2BADORA2APRMT6ADORA1 | |
| SCHEMBL918551 | 0.75 | ADORA2B (0.51) | ADORA2BADORA2AADORA1ADORA3TYMP | |
| SCHEMBL30679323 | 0.75 | TYMP (0.49) | ADORA2BADORA2APRMT6ADORA1TYMP | |
| SCHEMBL31208335 | 0.73 | ADORA2B (0.46) | ADORA2BADORA2APRMT6ADORA1ADORA3 | |
| SCHEMBL30657731 | 0.73 | TYMP (0.49) | ADORA2BADORA2AADORA1ADORA3TYMP | |
| SCHEMBL4304539 | 0.73 | TYMP (0.49) | ADORA2BADORA2AADORA1ADORA3TYMP | |
| SCHEMBL31208347 | 0.73 | ADORA2B (0.46) | ADORA2BADORA2APRMT6ADORA1ADORA3 | |
| SCHEMBL1067562 | 0.73 | ADORA2B (0.42) | ADORA2BADORA2APRMT6ADORA1ADORA3 | |
| SCHEMBL20773918 | 0.72 | ADORA2A (0.45) | ADORA2BADORA2APRMT6ADORA1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | SIRNA THERAPEUTICS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | NSUN3, IRF3, SNRPF | ADORA2B 1142/4885ADORA2A 1154/4885PRMT6 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.